18F-FCH (Fluorocholine)-PET/MR in Staging of High-Risk Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

18F-FCH-PET/MR in Staging of High-Risk Prostate Cancer: A Multiparametric Approach

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01993160
• Other study ID #: 18F-FCH-PET/MR
• Status: Completed
• Phase: N/A
• First received: October 25, 2013
• Last updated: January 12, 2017
• Start date: December 2013
• Est. completion date: December 2016

Study information

• Verified date: January 2017
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single centre, single arm feasibility study of 18FCH PET-MR imaging for staging patients with high risk prostate cancer.

Study Hypothesis:

FCH-PET/MR will enable more accurate staging of patients with high risk prostate cancer as compared to conventional imaging.

Description:

Up to 60% of patients treated with radical prostatectomy or external beam radiotherapy for prostate cancer will have biochemical failure at 5 years. This may be due to several reasons, including presence of sub-clinical metastases at time of local therapy.

Currently, patients with high risk prostate cancer are staged by MRI of the prostate (to assess local extent of disease), CT of the abdomen(to detect spread to lymph nodes) and bone scan (to assess for spread to bones). However, these standard imaging exams do not always identify all sites of disease. Recent research has suggested that performing positron emission tomography (PET) scanning with a tracer called fluorocholine (FCH) improves identification of lymph node and bone metastases in prostate cancer, resulting in more accurate diagnosis.

The main goal of this study is to find out whether staging high risk prostate cancer patients with FCH PET-CT and MRI of the whole body will improve detection of primary tumors and metastases compared to current standard imaging exams. Improved staging of patients with prostate cancer may impact patient care as it will help to select more appropriate therapy.

In this study, participants will undergo either combined PET/MRI or PET-CT and MRI after standard evaluations. The accuracy of each staging approach (standard vs. PET and MRI) will be evaluated. In addition, we will incorporate novel methods for data interpretation by creating imaging maps combining data from PET and MRI (termed "Multiparametric maps"). The goal of this novel approach is to find out whether mapping 2 or more characteristics of a tumor at the same time will improve tumor detection and accuracy of diagnosis.

About 40 men from the Princess Margaret Hospital will take part in this study. The study should take about 2 years to complete enrollment and the results should be known within 36 months of completion of enrollment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

• Age = 18 years

• Histologic diagnosis of carcinoma of prostate

• High risk disease: defined as Gleason =8, or T3 disease, or PSA >20ng/mL

• No prior therapy for prostate cancer (surgery, radiation therapy, hormone therapy, chemotherapy).

• Ability to provide written informed consent to participate in the study

Exclusion Criteria:

• Prior surgery or radiation therapy for prostate cancer

• Prior or ongoing hormone or other systemic therapy for prostate cancer

• Inability to lie supine for 90 minutes

• Any contraindication to MR as per Joint Department of Medical Imaging policies.

• Impaired kidney function with glomerular filtration rate < 30ml/min

• Previous anaphylactic reaction to gadolinium or other contraindications to MR.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Fluorocholine (18F-FCH) Injection
Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)

Radiation:
• PET scan
A whole body PET scan will be performed, integrated with either whole body low dose CT or whole body MRI
• Whole body MRI
A whole body MRI scan will be performed. This may be integrated with PET scan or performed separately.

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre, University Health Network, 610 University Ave.	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
University Health Network, Toronto	Prostate Cancer Canada Network

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Overall accuracy of multiparametric mapping of choline metabolism with various MR parameters in staging of patients with high risk prostate cancer as compared to conventional imaging strategies.		2 years
Other	Relationship of choline kinase activity in the primary tumor (as expressed by FCH uptake) to presence of hypoxia and expression of GLUT-1 transporter proteins in pathology specimens.		2 years
Primary	Number of prostate cancer foci detected with FCH PET/MR compared to MR alone.		2 years
Secondary	Detection rate of lymph node and distant metastases in patients with high risk prostate cancer as compared to conventional imaging strategies (CT abdomen and bone scintigraphy).		2 years